Ilya Tsimafeyeu
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Ilya Tsimafeyeu
Jun 12, 2024, 04:11 |
Insight
Nivolumab and Chemotherapy as First-Line Treatment for Metastatic Gastric Cancer: Updated Analysis and the Impact of FGFR2
"Nivolumab in combination with chemotherapy is the standard first-line treatment for metastatic gastric cancer expressing…
Jun 3, 2024, 15:09 |
Insight
Avelumab + Axitinib Did Not Improve Overall Survival in Patients with Metastatic Renal Cell Carcinoma: Don't Panic!
"Final overall survival (OS) and progression-free survival (PFS) results for patients with metastatic clear cell…
Oct 25, 2023, 17:52 |
Insight
Ilya Tsimafeyeu: Patients with metastatic renal cell carcinoma and high fibrinogen levels who received nivolumab had worse overall survival
Ilya Tsimafeyeu, Director at Bureau of Cancer ReĀsearch Russia, shared on Facebook: "Our study: Patients…
All:
3
Posts:
1 - 10
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Yardena Samuels: An absolute honor to be elected as the next EACR president
Facebook
RSS Feed
Twitter
Linkedin
Youtube